Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRABiotechnology
-$0.10 today
- Market cap
- $69.21M
- Beta
- 2.76
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$1.24
Volume 1.50M
Average 2.02M
NMRA Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Neumora Therapeutics, Inc. Common StockNASDAQ: NMRA
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables turns positive
Q1 FY2026 accounts payables was $1.68M, compared with -$2.26M a year earlier. Trailing-twelve-month accounts payables was $4M.
Context
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts payables holds near $1.68M or moves back toward the trailing-twelve-month quarterly average of $1M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 71K USD
- Year-over-year change
- -97.5%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 71K | -97.5% |
| FY2024 | 2024-12-31 | 2.87M | +594.5% |
| FY2023 | 2023-12-31 | (581K) | +53.4% |
| FY2022 | 2022-12-31 | (1.25M) | -64.2% |
| FY2021 | 2021-12-31 | (759K) | — |
Accounts Payables vs competitors
How NMRA compares with its peers on the latest reported figures
- NMRA's LTM Mar 2026 accounts payables of $4M is the 5th largest of the 10 companies compared; the peer median is $1.74M.
- Its year-over-year change of +845.6% is the 2nd highest of 10, against a peer median of -69.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $18.91M | +528.3% | — | 32.6% | |
| LTM Mar 2026 | $15.43M | -795.9% | — | 22.2% | |
| LTM Mar 2026 | $10.54M | +15832.8% | — | 11.9% | |
| LTM Mar 2026 | $10.3M | -925.0% | — | 13.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $4M | +845.6% | — | — |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $2.18M | +391.0% | — | 29.5% |
| LTM Mar 2026 | $1.74M | -181.3% | +289.5% | 1.9% | |
| LTM Mar 2026 | $1.2M | -69.6% | — | 1.9% | |
| LTM Mar 2026 | $979K | -84.6% | — | 9.9% | |
| LTM Mar 2026 | $943K | +140.1% | — | — | |
| Peer median (excluding NMRA) | $1.74M | -69.6% | +289.5% | 12.5% | |
Competitors are the stored peer set for NMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (237.31M) | (130.9M) | (235.93M) | (243.79M) | (236.93M) |
| Depreciation & Amortization | 538K | 594K | 668K | 631K | 208K |
| Deferred Income Tax | (53K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.27M | 8.3M | 17.24M | 39.99M | 29.88M |
| Change in Working Capital | (961K) | (6.95M) | (8.9M) | 22.64M | (437K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (759K) | (1.25M) | (581K) | 2.87M | 71K |
| Other Working Capital | (202K) | (5.7M) | (8.32M) | 19.76M | (508K) |
| Other Non-Cash Items | 158.09M | 14.06M | 63.64M | (1.78M) | 841K |
| Operating Cash Flow | (75.42M) | (114.9M) | (163.28M) | (182.94M) | (206.44M) |
| Capital Expenditures | (817K) | (511K) | (117K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | (775K) | 0 |
| Purchases of Investments | 0 | (226.37M) | (109.07M) | (312.22M) | (85.8M) |
| Sales of Investments | 0 | 71.87M | 178.17M | 242.44M | 251.17M |
| Other Investing Activities | 0 | (13M) | (4.59M) | 0 | 3.15M |
| Investing Cash Flow | (817K) | (168.01M) | 64.39M | (70.56M) | 168.52M |
| Debt Repayment | 0 | 0 | 0 | 0 | 57.16M |
| Common Stock Issued | 960K | 0 | 233.38M | 13.69M | 19.93M |
| Common Stock Repurchased | 0 | 0 | (491K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.37M | 3.53M | (948K) | 7.91M | 0 |
| Financing Cash Flow | 293.51M | 115.74M | 231.94M | 21.6M | 77.09M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 217.27M | (167.17M) | 133.05M | (231.89M) | 39.17M |
| Free Cash Flow | (76.24M) | (115.41M) | (163.4M) | (182.94M) | (206.44M) |
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
Intrinsic Alpha fair value
Locked
Current Price
$0.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.